Outcomes11

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 11 of 11

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4	Week 4	All randomized participants are included.	percentage of participants	NUMBER
SECONDARY	Achievement of vIGA-AD Success at Week 4 in Participants With Moderate Baseline Scores	Week 4	All randomized participants who were included in the moderate baseline vIGA-AD group during randomization are included.	percentage of participants	NUMBER
SECONDARY	vIGA-AD Success at Week 2	Week 2	All randomized participants are included.	percentage of participants	NUMBER
SECONDARY	vIGA-AD Success at Week 1	Week 1	All randomized participants are included.	percentage of participants	NUMBER
SECONDARY	Achievement of a 4-point Reduction at Week 4 in the Average, Weekly Worst Itch Numeric Rating Scale (WI-NRS) in Participants With Baseline WI-NRS Score ≥4	Week 4	All randomized participants who were ≥12 years of age, had an average weekly WI-NRS pruritus score ≥4 at baseline, and completed at least 4 of 7 evaluable daily WI-NRS questionnaires during the last 7 days of the Screening period are included. Multiple imputation was used to handle missing cases.	percentage of participants	NUMBER
SECONDARY	Achievement of a 4-point Reduction at Week 2 in the WI-NRS in Participants With Baseline WI-NRS Score ≥4	Week 2	All randomized participants who were ≥12 years of age, had an average weekly WI-NRS pruritus score ≥4 at baseline, and completed at least 4 of 7 evaluable daily WI-NRS questionnaires during the last 7 days of the Screening period are included. Multiple imputation was used to handle missing cases.	percentage of participants	NUMBER
SECONDARY	Achievement of a 4-point Reduction at Week 1 in the WI-NRS in Participants With Baseline WI-NRS Score ≥4	Week 1	All randomized participants who were ≥12 years of age, had an average weekly WI-NRS pruritus score ≥4 at baseline, and completed at least 4 of 7 evaluable daily WI-NRS questionnaires during the last 7 days of the Screening period are included. Multiple imputation was used to handle missing cases.	percentage of participants	NUMBER
SECONDARY	Achievement of ≥75% Decrease From Baseline at Week 4 in the Eczema Area and Severity Index (EASI-75)	Week 4	All randomized participants are included.	percentage of participants	NUMBER
SECONDARY	Achievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 4	Week 4	All randomized participants are included.	percentage of participants	NUMBER
SECONDARY	Achievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 2	Week 2	All randomized participants are included.	percentage of participants	NUMBER
SECONDARY	Achievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 1	Week 1	All randomized participants are included.	percentage of participants	NUMBER

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04773600/outcomes

API reference For AI assistants